BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 15240517)

  • 1. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.
    Fukuoka J; Fujii T; Shih JH; Dracheva T; Meerzaman D; Player A; Hong K; Settnek S; Gupta A; Buetow K; Hewitt S; Travis WD; Jen J
    Clin Cancer Res; 2004 Jul; 10(13):4314-24. PubMed ID: 15240517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.
    Reisman DN; Sciarrotta J; Wang W; Funkhouser WK; Weissman BE
    Cancer Res; 2003 Feb; 63(3):560-6. PubMed ID: 12566296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression.
    Reisman DN; Strobeck MW; Betz BL; Sciariotta J; Funkhouser W; Murchardt C; Yaniv M; Sherman LS; Knudsen ES; Weissman BE
    Oncogene; 2002 Feb; 21(8):1196-207. PubMed ID: 11850839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Turley H; Talks K; Pezzella F; Gatter KC; Harris AL
    Br J Cancer; 2001 Sep; 85(6):881-90. PubMed ID: 11556841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
    Sun A; Tawfik O; Gayed B; Thrasher JB; Hoestje S; Li C; Li B
    Prostate; 2007 Feb; 67(2):203-13. PubMed ID: 17075831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.
    Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C
    Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implication of cyclin B1 in non-small cell lung cancer.
    Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Kimura Y; Uchida Y
    Oncol Rep; 2003; 10(5):1381-6. PubMed ID: 12883711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer.
    Shibahara K; Sugio K; Osaki T; Uchiumi T; Maehara Y; Kohno K; Yasumoto K; Sugimachi K; Kuwano M
    Clin Cancer Res; 2001 Oct; 7(10):3151-5. PubMed ID: 11595709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRG1 loss in MiaPaCa2 cells induces an altered cellular morphology and disruption in the organization of the actin cytoskeleton.
    Rosson GB; Bartlett C; Reed W; Weissman BE
    J Cell Physiol; 2005 Nov; 205(2):286-94. PubMed ID: 15887247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines.
    Watanabe H; Mizutani T; Haraguchi T; Yamamichi N; Minoguchi S; Yamamichi-Nishina M; Mori N; Kameda T; Sugiyama T; Iba H
    Oncogene; 2006 Jan; 25(3):470-9. PubMed ID: 16247481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiƶ J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation.
    Banine F; Bartlett C; Gunawardena R; Muchardt C; Yaniv M; Knudsen ES; Weissman BE; Sherman LS
    Cancer Res; 2005 May; 65(9):3542-7. PubMed ID: 15867346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
    Glaros S; Cirrincione GM; Muchardt C; Kleer CG; Michael CW; Reisman D
    Oncogene; 2007 Oct; 26(49):7058-66. PubMed ID: 17546055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma.
    Endo M; Yasui K; Zen Y; Gen Y; Zen K; Tsuji K; Dohi O; Mitsuyoshi H; Tanaka S; Taniwaki M; Nakanuma Y; Arii S; Yoshikawa T
    Liver Int; 2013 Jan; 33(1):105-17. PubMed ID: 23088494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.
    Bria E; Visca P; Novelli F; Casini B; Diodoro MG; Perrone-Donnorso R; Botti C; Sperduti I; Facciolo F; Milella M; Cecere FL; Cognetti F; Mottolese M
    Eur J Surg Oncol; 2008 May; 34(5):593-8. PubMed ID: 17693049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic alterations of BRG1 leads to cancer development through its nuclear-cytoplasmic shuttling abnormalities.
    Gunduz E; Gunduz M; Nagatsuka H; Beder L; Demircan K; Tamamura R; Hatipoglu OF; Mahmut N; Katase N; Naomoto Y; Nagai N
    Med Hypotheses; 2006; 67(6):1313-6. PubMed ID: 16824695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung.
    O-charoenrat P; Rusch V; Talbot SG; Sarkaria I; Viale A; Socci N; Ngai I; Rao P; Singh B
    Clin Cancer Res; 2004 Sep; 10(17):5792-803. PubMed ID: 15355908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers.
    Au NH; Cheang M; Huntsman DG; Yorida E; Coldman A; Elliott WM; Bebb G; Flint J; English J; Gilks CB; Grimes HL
    J Pathol; 2004 Sep; 204(1):101-9. PubMed ID: 15307143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.